Eisai traded at 4,872.00 this Wednesday March 25th, increasing 63.00 or 1.31 percent since the previous trading session. Looking back, over the last four weeks, Eisai gained 5.58 percent. Over the last 12 months, its price rose by 12.75 percent. Looking ahead, we forecast Eisai to be priced at 4,558.67 by the end of this quarter and at 3,994.28 in one year, according to Trading Economics global macro models projections and analysts expectations.
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.